Lilly Gains, Compass Pathways Rises, Fermi Sinks After CEO, CFO Step Down

On this episode of Stock Movers:

-  Eli Lilly (LLY) shares sunk after the company agreed to buy Kelonia Therapeutics for as much as $7 billion, gaining access to a potential cutting-edge treatment for blood cancer.

- Compass Pathways (CMPS) shares higher after CBS reports that President Trump is set to sign an order as soon as this week that would signal willingness to further research the psychedelic drug ibogaine. 

- Fermi (FRMI) shares plunge after after the power company said its chief executive officer and chief financial officers have stepped down as the firm tries to secure its first customer.

See omnystudio.com/listener for privacy information.